Search
Polycarbophil
go.drugbank.com/drugs/DB09311ApprovedWithdrawnIt is insoluble in water, dilute acids, and dilute alkali.
Categories: Compounds used in a research, industrial, or household settingPiflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalProstate cancer is the most common non-cutaneous malignancy affecting men in North America[A235344] - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent … levels roughly 1000-fold greater than elsewhere in the body, and even higher in prostate cancer tissue.
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigationalSodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that … from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in
Categories: Compounds used in a research, industrial, or household settingClopenthixol
go.drugbank.com/drugs/DB13841InvestigationalIt is an antagonist at D1 and D2 dopamine receptors.
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193608] Use of selumetinib in this population has shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes. … [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved.
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalFood and Drug Administration approved sebetralstat on July 7, 2025, for treating acute HAE attacks in patients aged 12 years and older [L53533, L53538]. … This plasma kallikrein inhibitor works by reducing bradykinin, the substance that causes the characteristic swelling in HAE attacks [L53533]. The U.S.
Categories: Drugs Used in Hereditary AngioedemaSynonyms: 1H-Pyrazole-4-carboxamide, N-[(3-fluoro-4-methoxy-2-pyridinyl)methyl]-3-methoxymethyl)-1-[[4-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]methyl]-, N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1(2H)-yl)methyl]phenyl}methyl)-1H-pyrazol-4-carboxamideDioxybenzone
go.drugbank.com/drugs/DB11221ApprovedWithdrawnDioxybenzone is an approved sunscreen ingredient in concentrations up to 3% [L2525]. … Dioxybenzone, or benzophenone-8, is an organic compound derived from [DB01878] that is used as a sunscreen agent. It absorbed UV-B and UV-AII rays.
Pegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigational[L42725] It is advantageous over currently available management therapies for PKU, such as [DB00360], that are ineffective to many patients due to long-term adherence issues or inadequate Phe-lowering … Phenylketonuria is a rare autosomal recessive disorder that is characterized by deficiency of the enzyme phenylalanine hydroxylase (PAH) [A33284] and affects about 1 in 10,000 to 15,000 people in the United
Pemivibart
go.drugbank.com/drugs/DB18720Investigational[L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728] … [L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.
Vanoxerine
go.drugbank.com/drugs/DB03701InvestigationalIt was synthesized in the late 1970s and developed as a potential treatment for depression. … [A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use.